Adlai Nortye Ltd.
ANL
Rank in Stocks
#17331
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the... Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.
Share Price
$10.85
Last synced: 2026-11-11
Market Cap
$172.75M
Change (1 day)
8.94%
Change (1 year)
573.91%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Adlai Nortye Ltd. (ANL)
Category
Healthcare
EPS for Adlai Nortye Ltd. (ANL)
EPS as of June 2026 TTM: $-1.95
According to Adlai Nortye Ltd.'s latest financial reports, its current EPS (TTM) is $-1.95. At the end of 2025 the company had an EPS of $-3.33, an increase over its 2024 EPS of $-4.89.
EPS history for Adlai Nortye Ltd. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.95 | -41.44% |
| 2025 | $-3.33 | -31.90% |
| 2024 | $-4.89 | -68.29% |
| 2023 | $-15.42 | 223.27% |
| 2022 | $-4.77 | 3.25% |
| 2021 | $-4.62 | -39.37% |
| 2020 | $-7.62 | 262.86% |
| 2019 | $-2.10 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -903.08% |
US
|
|
| $-7.07 | 262.56% |
US
|
|
| $-5.29 | 171.28% |
AU
|
|
| $12.88 | -760.52% |
BE
|
|
| $21.56 | -1,205.64% |
NL
|
Questions about Adlai Nortye Ltd.'s earnings per share (EPS)
What is Adlai Nortye Ltd.'s earnings per share (EPS)?
Adlai Nortye Ltd.'s earnings per share (EPS) over the last twelve months is $-1.95, as of Jun 2026.
What was Adlai Nortye Ltd.'s earnings per share (EPS) in 2025?
In 2025, Adlai Nortye Ltd.'s earnings per share (EPS) was $-3.33, compared with $-4.89 in 2024.
How has Adlai Nortye Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Adlai Nortye Ltd.'s earnings per share (EPS) was highest in 2025 ($-3.33) and lowest in 2023 ($-15.42).
How does Adlai Nortye Ltd.'s earnings per share (EPS) compare with similar companies?
Adlai Nortye Ltd.'s earnings per share (EPS) ($-1.95) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.